Wall Street analysts expect Intra-Cellular Therapies Inc (NASDAQ:ITCI) to post earnings per share (EPS) of ($0.85) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Intra-Cellular Therapies’ earnings, with estimates ranging from ($0.92) to ($0.74). Intra-Cellular Therapies reported earnings of ($0.53) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 60.4%. The company is scheduled to issue its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that Intra-Cellular Therapies will report full year earnings of ($3.15) per share for the current year, with EPS estimates ranging from ($3.40) to ($2.88). For the next financial year, analysts forecast that the company will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.89) to ($3.24). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08.

A number of analysts have recently weighed in on ITCI shares. Cantor Fitzgerald started coverage on shares of Intra-Cellular Therapies in a report on Thursday, August 23rd. They issued an “overweight” rating and a $32.00 price target on the stock. ValuEngine upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. BidaskClub cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Royal Bank of Canada restated a “buy” rating and issued a $35.00 price target on shares of Intra-Cellular Therapies in a report on Friday, August 3rd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $28.00.

Shares of NASDAQ:ITCI traded down $0.52 during trading on Thursday, reaching $18.21. The stock had a trading volume of 192,528 shares, compared to its average volume of 348,816. Intra-Cellular Therapies has a one year low of $13.93 and a one year high of $25.82.

A number of hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in Intra-Cellular Therapies by 9.4% in the 2nd quarter. Northern Trust Corp now owns 540,016 shares of the biopharmaceutical company’s stock worth $9,542,000 after purchasing an additional 46,453 shares in the last quarter. Schroder Investment Management Group acquired a new stake in Intra-Cellular Therapies in the 2nd quarter worth approximately $21,222,000. California Public Employees Retirement System boosted its stake in Intra-Cellular Therapies by 15.0% in the 2nd quarter. California Public Employees Retirement System now owns 59,105 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 7,705 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in Intra-Cellular Therapies by 53.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 3,339 shares in the last quarter. Finally, Raymond James & Associates boosted its stake in Intra-Cellular Therapies by 33.0% in the 2nd quarter. Raymond James & Associates now owns 64,150 shares of the biopharmaceutical company’s stock worth $1,134,000 after purchasing an additional 15,918 shares in the last quarter. Institutional investors own 71.41% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.